PD173074

For research use only.

Licensed by Pfizer Catalog No.S1264

76 publications

PD173074 Chemical Structure

CAS No. 219580-11-7

PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src. PD173074 reduces proliferation and promotes apoptosis in gastric cancer cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 98 In stock
USD 70 In stock
USD 120 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's PD173074 has been cited by 76 publications

Purity & Quality Control

Choose Selective FGFR Inhibitors

Biological Activity

Description PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src. PD173074 reduces proliferation and promotes apoptosis in gastric cancer cells.
Targets
FGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
~25 nM 100 nM-200 nM
In vitro

PD173074 is an ATP-competitive inhibitor of FGFR1 with Ki of ~40 nM. PD173074 is also an effective inhibitor of VEGFR2. Compared to FGFR1, PD173074 weakly inhibits the activities of Src, InsR, EGFR, PDGFR, MEK, and PKC with 1000-fold or greater IC50 values. PD173074 inhibits autophosphorylation of FGFR1 and VEGFR2 in a dose-dependent manner with IC50 of 1-5 nM and 100-200 nM, respectively. [1] PD173074 inhibits FGF-2 promotion of granule neuron survival in a dose-dependent manner with IC50 of 12 nM, exhibiting 1,000-fold greater potency than that of SU 5402. [2] PD173074 specifically inhibits FGF-2-mediated effects on proliferation, differentiation, and MAPK activation in oligodendrocyte (OL) lineage cells. [3] PD173074 is active against the WT receptor and FGFR3 mutations in multiple myeloma (MM) cell lines. PD173074 also potently inhibits autophosphorylation of FGFR3 in a dose-dependent manner with IC50 of ~5 nM. PD173074 treatment potently reduces viability of FGFR3-expressing KMS11 and KMS18 cells with IC50 of <20 nM. Inhibition of aFGF-stimulated MM cell growth by PD173074 is highly correlated with the expression of FGFR3. PD173074 treatment completely abolishes NIH 3T3 transformation mediated by Y373C FGFR3 but not by Ras V12, demonstrating that PD173074 specifically targets FGFR3-mediated cell transformation and lacks nonspecific cytotoxic effect. PD173074 also induces functional maturation of KMS11 and KMS18 cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H1581 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwMEGyNlUh|ryP MUXTRW5ITVJ?
KG-1 NW\0emFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\lUmlEPTB;MD6wOVEzQSEQvF2= NYLnbVQyW0GQR1XS
MFM-223 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV23[oRUUUN3ME2wMlIyPTd4IN88US=> NHj6c4RUSU6JRWK=
EoL-1-cell NFW0ZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fJNmlEPTB;MD6zNlk5PCEQvF2= MmfRV2FPT0WU
ECC10 NV2wPFA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYraN4J[UUN3ME2wMlM{QDl6IN88US=> M4SwcHNCVkeHUh?=
H-EMC-SS MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEOzeHhKSzVyPUCuN|Q4OTVizszN Mn76V2FPT0WU
AN3-CA NVf5WHYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwNECxN|Mh|ryP M4DWOHNCVkeHUh?=
HuO-3N1 M3PPXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwNUS2OVMh|ryP MWHTRW5ITVJ?
RT-112 NE\mSIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HScGlEPTB;MD61OFcxOSEQvF2= MWnTRW5ITVJ?
NEC8 M4rkfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwNU[yPFkh|ryP MYDTRW5ITVJ?
D-263MG M1TVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVf4UXVzUUN3ME2wMlcyOTV7IN88US=> NGDQZYNUSU6JRWK=
SW962 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwN{i5PFgh|ryP Ml;FV2FPT0WU
BV-173 MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEP1TodKSzVyPUCuPFQ3OjNizszN M1vpRnNCVkeHUh?=
MFE-280 NYruVYpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC3eGpiUUN3ME2wMlg2QDd{IN88US=> MWrTRW5ITVJ?
HuH-7 NXrE[4JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn36TWM2OD1zLkK0OFY1KM7:TR?= MXHTRW5ITVJ?
RS4-11 NHHaSm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXjeoFKSzVyPUGuN|M5QDZizszN MV\TRW5ITVJ?
DMS-114 M4PwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\oV2lEPTB;MT6zOlc{PyEQvF2= M1PUPHNCVkeHUh?=
MSTO-211H MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml24TWM2OD1zLkS3N|c5KM7:TR?= MUjTRW5ITVJ?
DU-145 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGCxNXFKSzVyPUGuOVgzOTdizszN NEfwZppUSU6JRWK=
A172 NXO5PYtsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXqTWM2OD1zLkewN|U2KM7:TR?= NFXocVdUSU6JRWK=
SBC-1 NVq4UFlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJwMEm0JO69VQ>? NUXNTIdqW0GQR1XS
H9 NFew[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\hcGlEPTB;Mj6xOFMxPiEQvF2= NX32cYx5W0GQR1XS
NCI-SNU-1 M4f0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJwMUizPVQh|ryP MWPTRW5ITVJ?
NCI-H720 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPGd5A{UUN3ME2yMlIyOjh|IN88US=> NX\SSIpOW0GQR1XS
HCC2218 NULkfmllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLDTWM2OD1{LkO3PVM6KM7:TR?= M2n0WnNCVkeHUh?=
G-401 M1rFOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jvfGlEPTB;Mj60O|E5QSEQvF2= NIjOPWNUSU6JRWK=
MPP-89 M1fzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLCTWM2OD1{LkS4N|Y1KM7:TR?= MVzTRW5ITVJ?
697 M4jNc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\aW2lEPTB;Mj62OVM{OSEQvF2= NFPVflNUSU6JRWK=
KARPAS-45 NGPmcVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWGwc3V7UUN3ME2yMlcxPzR5IN88US=> MYLTRW5ITVJ?
MG-63 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zMfmlEPTB;Mj65OFI3OiEQvF2= M{XQPXNCVkeHUh?=
NTERA-S-cl-D1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTNwMEO0O|Ih|ryP MoXuV2FPT0WU
G-402 NG[0NGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7EV4NGUUN3ME2zMlEzPzJ5IN88US=> MofJV2FPT0WU
NKM-1 M13CfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Sxd2lEPTB;Mz6xN|U3PCEQvF2= M{PrOXNCVkeHUh?=
RH-18 NHvzcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTNwMUm1PVgh|ryP M{jzenNCVkeHUh?=
NCI-H1092 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoiwTWM2OD1|LkG5Olkh|ryP MnPJV2FPT0WU
RPMI-8226 NYTZWIFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXz2OGltUUN3ME2zMlI{PDR5IN88US=> NFznUYVUSU6JRWK=
GAMG M3Lt[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTnTWM2OD1|LkS2OVc3KM7:TR?= NUHoT5BiW0GQR1XS
HH NXP3NlJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTNwNEe2O|Yh|ryP MUHTRW5ITVJ?
RO82-W-1 MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnTZodKSzVyPUOuOFk5PTVizszN Mn;KV2FPT0WU
CCRF-CEM MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjUfIJKSzVyPUOuOVA1QDhizszN MmS2V2FPT0WU
NBsusSR MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTNwNkO5Olkh|ryP MUDTRW5ITVJ?
CHL-1 MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIT6PZNKSzVyPUOuOlU4QTlizszN NX22bWVuW0GQR1XS
LK-2 NIXt[ndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHkTWM2OD1|Lk[3NVM{KM7:TR?= NIDoZ4lUSU6JRWK=
Hs-578-T NULWSGJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TxbWlEPTB;Mz62O|g4OyEQvF2= MojsV2FPT0WU
CTB-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDobmJKSzVyPUOuPFAxPTFizszN MmGwV2FPT0WU
ES5 NX7adnNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\GR2ZxUUN3ME2zMlg{PjN5IN88US=> MUDTRW5ITVJ?
A204 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDFc5Y1UUN3ME2zMlkzODd3IN88US=> MYXTRW5ITVJ?
SW780 MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTNwOUKyOFUh|ryP NFfjbpNUSU6JRWK=
EW-3 MmTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TrbWlEPTB;Mz65PFkzOyEQvF2= NGL0b3hUSU6JRWK=
A704 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nEWmlEPTB;ND6yPFczOyEQvF2= MX3TRW5ITVJ?
LU-139 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\MZnUzUUN3ME20MlMyPTN2IN88US=> NXu3SoN4W0GQR1XS
CAL-72 M2rVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3i1XWlEPTB;ND60NVc1PiEQvF2= MXLTRW5ITVJ?
D-336MG NF76W4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTRwNE[4NVch|ryP MkWxV2FPT0WU
LAMA-84 NEPZ[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnu5TWM2OD12LkWzN|Eh|ryP MoXnV2FPT0WU
GI-ME-N NWPue2VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHxXFBKSzVyPUSuOVQ5OSEQvF2= M3npfnNCVkeHUh?=
KM-H2 NUTheHV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmGyTWM2OD12LkW1NlIzKM7:TR?= MYrTRW5ITVJ?
NCI-H209 NILUVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TLfGlEPTB;ND61PFI5OyEQvF2= NFnxRWxUSU6JRWK=
IGROV-1 Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2H5eGlEPTB;ND64O|E3QCEQvF2= NETWVZJUSU6JRWK=
L-363 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rjS2lEPTB;ND65OlY3PSEQvF2= NV7RVZNvW0GQR1XS
SK-MEL-3 NXT4fXBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjnclRKSzVyPUWuNlQxPiEQvF2= NVXxTmxOW0GQR1XS
HuO9 NInRSXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDxTWM2OD13LkO4PFQ{KM7:TR?= MXPTRW5ITVJ?
NOS-1 M17KUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPQfGREUUN3ME21MlczQTJ5IN88US=> MWTTRW5ITVJ?
NCI-H1770 MmXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3SU|ZLUUN3ME21Mlk2ODN{IN88US=> NIf3UWtUSU6JRWK=
SF126 NVTFNm5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHS4V3JKSzVyPU[uNlE1ODZizszN Mn7wV2FPT0WU
ML-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHq3XlJKSzVyPU[uNlQ6PzdizszN NUnxUINkW0GQR1XS
CHP-134 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1y3bGlEPTB;Nj6yOVE5OiEQvF2= NYrUbnFHW0GQR1XS
NCI-H1355 M{XyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPYTnZ{UUN3ME22MlQyPzN|IN88US=> M2rDc3NCVkeHUh?=
TE-12 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTZwN{K2O|Eh|ryP MVrTRW5ITVJ?
A4-Fuk MlvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4OwfWlEPTB;Nj63N|E1OiEQvF2= M13DVHNCVkeHUh?=
MV-4-11 NE[zeZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\GZ5JKSzVyPU[uO|Y3OjZizszN MW\TRW5ITVJ?
SK-UT-1 M2GwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTZwOUG3PFQh|ryP Mn74V2FPT0WU
J-RT3-T3-5 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXLTWM2OD15LkC3O|Y1KM7:TR?= NXnkN5pWW0GQR1XS
ME-180 NELFeZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\5TWM2OD15LkGwOFA1KM7:TR?= NUXQTYxQW0GQR1XS
SK-MEL-28 Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTdwM{e4NVkh|ryP NFHKT2FUSU6JRWK=
HAL-01 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlq0TWM2OD15LkS4N|QyKM7:TR?= Mn36V2FPT0WU
ES8 NIm0dXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfEN|VKSzVyPUeuOlk3OjZizszN MmjSV2FPT0WU
DB MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRThwMUG1NFQh|ryP NVL0[Gg{W0GQR1XS
SK-NEP-1 MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfmXldiUUN3ME24MlQ5OTR7IN88US=> MkLGV2FPT0WU
COR-L88 MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzKTWM2OD16LkWwPVgyKM7:TR?= MVXTRW5ITVJ?
LB1047-RCC NGLBWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvYTWM2OD16LkWyNlEzKM7:TR?= NUjYOXRqW0GQR1XS
NCI-H520 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\aNY9KSzVyPUiuOlIyPTdizszN NXPFe4FlW0GQR1XS
SW954 NEPmWVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LNXGlEPTB;OD62PVc5PiEQvF2= NEXqWpNUSU6JRWK=
TE-6 NF71OY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jpbWlEPTB;OD63OVE1OyEQvF2= M4TCT3NCVkeHUh?=
D-283MED M3rvZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPOSWYxUUN3ME25MlA3PTN2IN88US=> MYHTRW5ITVJ?
DBTRG-05MG NVLSeIZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTlwMEm2NFch|ryP NYnpNWxWW0GQR1XS
NCI-H446 MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjITWM2OD17LkK5OVI3KM7:TR?= MmSyV2FPT0WU
HOS M4fV[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTlwM{WxN|Qh|ryP MmHXV2FPT0WU
ES4 MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTlwNUC1PVUh|ryP NV74VZhxW0GQR1XS
EW-13 NIDoWW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmmzTWM2OD17Lki5NFU2KM7:TR?= Ml72V2FPT0WU
IST-MES1 NGD0bFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPQWZdKSzVyPUmuPVQ2OzRizszN MXTTRW5ITVJ?
CAS-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvnR|ZnUUN3ME25Mlk4PjV7IN88US=> MmTWV2FPT0WU
EM-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPMd2RKSzVyPUGwMlE{QTNizszN NYn6SVB2W0GQR1XS
SW948 NFr3ToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjuNFBKSzVyPUGwMlE5QDJizszN MVvTRW5ITVJ?
OAW-42 M3fQNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTFyLkWyOlch|ryP MYDTRW5ITVJ?
BE-13 NFfNZ5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkm3TWM2OD1zMD62OVc3KM7:TR?= M2\YdHNCVkeHUh?=
KU812 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTFyLkezPVEh|ryP MmPzV2FPT0WU
SK-MEL-30 NE\q[nNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnsTWM2OD1zMD64PVAyKM7:TR?= NGHWTYxUSU6JRWK=
A2780 NVrYTVBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGCx[2VKSzVyPUGxMlA{ODhizszN NYD1TIFEW0GQR1XS
TGBC24TKB MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTFzLkC3N|ch|ryP MljVV2FPT0WU
GOTO M1i2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHVTWM2OD1zMT6yNFg1KM7:TR?= NIjhdWFUSU6JRWK=
NCI-H526 NH2wbJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jhTWlEPTB;MUGuN|g{PyEQvF2= NYfhZlNFW0GQR1XS
BHT-101 NUi0fW5vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;GUXc3UUN3ME2xNU41PDV4IN88US=> M3zGdnNCVkeHUh?=
NCI-H1155 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPtUllKUUN3ME2xNU41QTR5IN88US=> NUezVHpKW0GQR1XS
MCF7 M1Lldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFzLk[xOlch|ryP MUXTRW5ITVJ?
MKN45 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3m2[WlEPTB;MUGuO|k6OyEQvF2= MkHoV2FPT0WU
MOLT-16 NW\m[|hMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnL5TWM2OD1zMT65OlkzKM7:TR?= NFPD[YJUSU6JRWK=
YH-13 MoPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XKUGlEPTB;MUKuNFM1PiEQvF2= MVHTRW5ITVJ?
P12-ICHIKAWA NWXDVJIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlG1TWM2OD1zMj6zPFQ2KM7:TR?= Mk\nV2FPT0WU
GR-ST MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDwb3dSUUN3ME2xNk42Ojl3IN88US=> MlP1V2FPT0WU
CAKI-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlO0TWM2OD1zMj63PVEh|ryP M1fQcHNCVkeHUh?=
LXF-289 M17yVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTF|LkC4N|Uh|ryP MoDqV2FPT0WU
MHH-PREB-1 M2\wdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3H6V2lEPTB;MUOuNlcxPCEQvF2= MorFV2FPT0WU
EW-16 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTF|LkOxPFch|ryP NIj5co5USU6JRWK=
NCI-H82 NG\1b4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGi0PYNKSzVyPUGzMlQyQTVizszN MWnTRW5ITVJ?
MMAC-SF NImwPGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XEeWlEPTB;MUOuOFU1PyEQvF2= M2nIVXNCVkeHUh?=
COLO-684 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fkWmlEPTB;MUOuOVMyQCEQvF2= NUTUU2tSW0GQR1XS
QIMR-WIL MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTF|LkixNFkh|ryP MnzGV2FPT0WU
NB69 M{LVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;NR3JKSzVyPUGzMlk5PjhizszN MUXTRW5ITVJ?
NCI-H2291 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFmwOnhKSzVyPUG0MlQ1PTNizszN MVPTRW5ITVJ?
MKN7 NVTEXFNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M160UmlEPTB;MUSuOlY4PiEQvF2= MVLTRW5ITVJ?
HDLM-2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH1TWM2OD1zNT6xNlg3KM7:TR?= Ml7lV2FPT0WU
A253 NG\5NYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDaTWM2OD1zNT6zPFY6KM7:TR?= NYLWXmp{W0GQR1XS
SK-LU-1 M3;jN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fEOmlEPTB;MUWuPVA6PCEQvF2= M3;PWXNCVkeHUh?=
MEG-01 M{HlPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLy[oFvUUN3ME2xOU46OTB5IN88US=> NH;EfJlUSU6JRWK=
SK-N-DZ MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTF3LkmzO|Yh|ryP NHrWS5hUSU6JRWK=
H4 M{X3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjRd49vUUN3ME2xOk4xQDhizszN NWjIO2dpW0GQR1XS
LU-65 MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rtSWlEPTB;MU[uN|M5PCEQvF2= MU\TRW5ITVJ?
NCI-H1048 NIDtbpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTmc5lKSzVyPUG2MlUyPjVizszN M{PZPXNCVkeHUh?=
LCLC-97TM1 M1POSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LUT2lEPTB;MU[uOVg5QSEQvF2= MWnTRW5ITVJ?
CAL-120 NV20[mtnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPjOXg4UUN3ME2xOk46QDd7IN88US=> MYjTRW5ITVJ?
LU-134-A Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYD3cGxJUUN3ME2xO{4{OzlzIN88US=> NIPDNolUSU6JRWK=
SK-MEL-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYqy[5pFUUN3ME2xO{44OTJ5IN88US=> M2OxbXNCVkeHUh?=
NCI-H69 MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;QNZFKSzVyPUG3Mlk{ODdizszN MVHTRW5ITVJ?
MC116 M3Gxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XC[mlEPTB;MUeuPVc2KM7:TR?= M{PBNXNCVkeHUh?=
UMC-11 MljIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTF6LkG3PFgh|ryP NGS4NG1USU6JRWK=
HCC1395 NGntboVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zPWmlEPTB;MUiuOFMxOSEQvF2= MYTTRW5ITVJ?
no-10 NUnSb21OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrh[HFqUUN3ME2xPE43Ozh6IN88US=> MlrtV2FPT0WU
NY NXrxO4gxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjlWlFVUUN3ME2xPU4xQDB7IN88US=> MljCV2FPT0WU
OS-RC-2 M3n3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPBSJJKSzVyPUG5MlEzPTJizszN NHvWR2NUSU6JRWK=
D-423MG M1e3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXexdIRwUUN3ME2xPU4{QTV{IN88US=> MnPaV2FPT0WU
LC-2-ad NVTrN2s{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XZSWlEPTB;MUmuO|YyOiEQvF2= NXHrVmMzW0GQR1XS
DU-4475 NVHH[HdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HacWlEPTB;MUmuPFg2OiEQvF2= MkjZV2FPT0WU
YKG-1 NELmXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK1dWJJUUN3ME2xPU46PjJizszN NF;zSGVUSU6JRWK=
HCC1569 M1vvd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPKSJBKSzVyPUKwMlI3OjRizszN NWD4bVhRW0GQR1XS
TYK-nu NFrvVINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHn3N5ZKSzVyPUKwMlI5PDdizszN MWfTRW5ITVJ?
DEL MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHwTWM2OD1{MD65PFA5KM7:TR?= NFzvZXdUSU6JRWK=
MHH-ES-1 M3rBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJzLkO1PVch|ryP NHzIUpVUSU6JRWK=
KARPAS-299 NInMW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJzLkWyPUDPxE1? NX3TR3pWW0GQR1XS
CTV-1 NX7tUI82T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NES1OJhKSzVyPUKxMlYyPzJizszN NF;qT4tUSU6JRWK=
NCI-H2452 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTJ{Lk[2O|ch|ryP MVPTRW5ITVJ?
D-566MG Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvXfGJKSzVyPUKyMlc3ODFizszN NWPjVlZ{W0GQR1XS
EFO-27 MnrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTUTWM2OD1{Mz6wOlUyKM7:TR?= M33VNHNCVkeHUh?=
NCI-H596 NGPHNpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzGRm9iUUN3ME2yN{45PTJ5IN88US=> NYH3N2NTW0GQR1XS
KS-1 NXrIcYN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHL5eGRKSzVyPUK0MlI4PTlizszN MXTTRW5ITVJ?
8305C MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjHWHpKSzVyPUK0MlQxPDVizszN MnvDV2FPT0WU
A427 M1XkZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nyV2lEPTB;MkWuNFMzOyEQvF2= MY\TRW5ITVJ?
COLO-800 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInOTHpKSzVyPUK1MlExPjFizszN MonRV2FPT0WU
SJRH30 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PCb2lEPTB;MkWuN|kxQCEQvF2= NIm5SIlUSU6JRWK=
MEL-HO NIe1T2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjqcmczUUN3ME2yOU41OzF7IN88US=> NH;he5ZUSU6JRWK=
FTC-133 NFrDcIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\nfVlMUUN3ME2yOU45OTh4IN88US=> M4Hmc3NCVkeHUh?=
SF295 MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTJ4LkK5OkDPxE1? NWDlT2FNW0GQR1XS
SW1710 NYfr[HJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HqR2lEPTB;Mk[uOFEzOyEQvF2= MmHVV2FPT0WU
EFM-19 M3vNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXmTWM2OD1{Nj64NVQ2KM7:TR?= MUHTRW5ITVJ?
NB10 NYPFOmpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jjT2lEPTB;MkiuNlI6PyEQvF2= NFjJ[4xUSU6JRWK=
TK10 NXu1e4p6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnj2TWM2OD1{OD6yN|k6KM7:TR?= MoDjV2FPT0WU
D-502MG Mo\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTJ6LkSg{txO NUe0bWZFW0GQR1XS
EW-18 NF\vZmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDWTWM2OD1{OD60N|g3KM7:TR?= NH7MbVJUSU6JRWK=
VMRC-RCZ NVrQOoQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjhbYtKSzVyPUK4Mlk1OSEQvF2= M{XH[HNCVkeHUh?=
Ca9-22 MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlK0TWM2OD1{OT60OVU4KM7:TR?= NGrX[ZZUSU6JRWK=
KYSE-70 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTJ7LkW3PFYh|ryP NWe2SGp1W0GQR1XS
A101D MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDLUYFKSzVyPUK5MlY1PzJizszN Mmj3V2FPT0WU
WM-115 M{nBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;rTHNKSzVyPUK5Mlc3ODdizszN MoPFV2FPT0WU
HCC2157 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTJ7Lki4NFch|ryP M3f0NHNCVkeHUh?=
TE-9 NFHqT|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrjVXJqUUN3ME2yPU45QDZ3IN88US=> MUjTRW5ITVJ?
K-562 MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonVTWM2OD1|MD6wPVM{KM7:TR?= NELEXHNUSU6JRWK=
SN12C NH:5bopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\XTWM2OD1|MD6xOFI3KM7:TR?= M3SxSXNCVkeHUh?=
ESS-1 M1iy[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTNyLkS3OVkh|ryP MmLQV2FPT0WU
K5 MnW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TEXmlEPTB;M{CuO|Y1KM7:TR?= NXSzbHRqW0GQR1XS
J82 NUDRdpFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXG3TYltUUN3ME2zNU4xQDl5IN88US=> NED5cnFUSU6JRWK=
HOP-92 M1v2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGS5RVhKSzVyPUOxMlEyOTFizszN MWjTRW5ITVJ?
NCI-H2228 NHfsdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTNzLkOyPVYh|ryP NIHKUpdUSU6JRWK=
OCI-AML2 M17FeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTNzLkO2NUDPxE1? MXXTRW5ITVJ?
NCI-SNU-5 M3ixV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DyPWlEPTB;M{GuPFE{PyEQvF2= MWHTRW5ITVJ?
A3-KAW NUHaVpFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGftUYtKSzVyPUOxMlkzPDNizszN MX;TRW5ITVJ?
LCLC-103H NVjqVVB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknoTWM2OD1|Mj6wNVcyKM7:TR?= MV3TRW5ITVJ?
KY821 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHCTWM2OD1|Mj62PFg1KM7:TR?= MVjTRW5ITVJ?
JVM-2 NYf2NG1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFW4OFZKSzVyPUOyMlkxPzlizszN M2TSdXNCVkeHUh?=
Mo-T MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zoOmlEPTB;M{OuNVAxPSEQvF2= MorkV2FPT0WU
IA-LM MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTN|LkK3OUDPxE1? MXzTRW5ITVJ?
C8166 NIi0[ZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHsbZJRUUN3ME2zN{4{OTl{IN88US=> NHzoUYtUSU6JRWK=
TCCSUP Mlj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTN|LkSzNFch|ryP MmjTV2FPT0WU
JEG-3 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzNfVV{UUN3ME2zN{41PzZ6IN88US=> NIfUd|FUSU6JRWK=
MS-1 NXX1OJF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDVTWM2OD1|Mz61OVUyKM7:TR?= NXOzdpBNW0GQR1XS
NCI-H1304 M1m2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfmTWM2OD1|Mz61O|I2KM7:TR?= NYHa[HlXW0GQR1XS
Ramos-2G6-4C10 NHLRRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M36zcGlEPTB;M{SuNFM{PSEQvF2= MVTTRW5ITVJ?
MDA-MB-453 NXfOWmNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTN2Lk[zPVUh|ryP MnflV2FPT0WU
KYSE-520 MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnsVGxKSzVyPUO0MlcyQDFizszN NI\WfoZUSU6JRWK=
SW900 NUfHTpg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknRTWM2OD1|ND64NVE2KM7:TR?= MVXTRW5ITVJ?
HCC2998 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTN3LkG1Nlkh|ryP Mmi1V2FPT0WU
A2058 NUi2c2t2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTN3Lk[wOlEh|ryP MnXpV2FPT0WU
OVCAR-3 M2W1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvFTW0yUUN3ME2zOk4zODR3IN88US=> M13ZcHNCVkeHUh?=
MOLT-4 MnfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vKS2lEPTB;M{[uNlI6PCEQvF2= M{j6NnNCVkeHUh?=
CAPAN-1 MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTN4LkS2PVkh|ryP MVXTRW5ITVJ?
SCC-9 NEf0TpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7Ee29KSzVyPUO3MlQxOjdizszN MWrTRW5ITVJ?
SF268 NXXITmV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3UeYp1UUN3ME2zPE4{PDN|IN88US=> MnjkV2FPT0WU
HGC-27 NV64ZYV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;LTnBDUUN3ME2zPE4{PzFzIN88US=> M3qwXnNCVkeHUh?=
DOHH-2 NGTxW3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHCNZVVUUN3ME2zPE44OTV6IN88US=> NEP3c2JUSU6JRWK=
KE-37 NFTSRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL0TWM2OD1|OD65PFI5KM7:TR?= NEjqW4hUSU6JRWK=
MOLT-13 MlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTN7LkK1NFIh|ryP MXvTRW5ITVJ?
ES1 NHzwUpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHzOIxvUUN3ME2zPU4{QDVizszN MnTlV2FPT0WU
SK-OV-3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETI[3ZKSzVyPUO5Mlk3PDNizszN M3nlbHNCVkeHUh?=
SNU-449 NIjpblBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTJSmMyUUN3ME20NE4xPzZ2IN88US=> M{W2fXNCVkeHUh?=
KYSE-510 M1fVXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nNbGlEPTB;NECuNVI6PSEQvF2= MWPTRW5ITVJ?
HL-60 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHi3OGNKSzVyPUSwMlk4QDNizszN NYCwdWh1W0GQR1XS
DJM-1 M4XMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nxWWlEPTB;NECuPVc6QSEQvF2= MkD6V2FPT0WU
TGBC11TKB MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPvTWM2OD12MT6wPVI3KM7:TR?= NGe1[YNUSU6JRWK=
U-2-OS MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHGOVlKSzVyPUSyMlI3PDFizszN Ml7uV2FPT0WU
NCI-H2030 NV3CPVR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFT1SZpKSzVyPUSyMlQ{PjhizszN NH6yS41USU6JRWK=
LU-135 Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7zcmFxUUN3ME20Nk42PDR5IN88US=> MXfTRW5ITVJ?
ZR-75-30 NI\yRoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17Qb2lEPTB;NEOuNFQ6OyEQvF2= NFnnc2pUSU6JRWK=
GT3TKB NF;6dWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mor1TWM2OD12Mz6yOlc6KM7:TR?= M{\wcnNCVkeHUh?=
RPMI-2650 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDje|RWUUN3ME20N{44QDF4IN88US=> NGG3bG1USU6JRWK=
SAS MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;LPGlEPTB;NEOuPVU{PCEQvF2= M1i2bXNCVkeHUh?=
MDA-MB-231 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvLV2Q1UUN3ME20N{46PjB7IN88US=> MlnKV2FPT0WU
JVM-3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTR2LkC1N|Mh|ryP MkHrV2FPT0WU
COLO-320-HSR NHi2PZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzaTWM2OD12ND61OlM{KM7:TR?= MUTTRW5ITVJ?
SNB75 Ml:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTR2Lk[xNFUh|ryP M1f3UHNCVkeHUh?=
NCI-H441 MnGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkexTWM2OD12ND65N|I5KM7:TR?= M2\0d3NCVkeHUh?=
HCT-116 M1O2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TtTWlEPTB;NESuPVg3QCEQvF2= NIPveYVUSU6JRWK=
NCI-H226 M{\XZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTR3Lk[zOlgh|ryP NFjROmpUSU6JRWK=
CAL-33 M4rseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHCO3dKSzVyPUS1MlkzOTdizszN MVnTRW5ITVJ?
NCI-H1437 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:2b2lEPTB;NE[uN|IyKM7:TR?= MYfTRW5ITVJ?
HCC1187 NUPJOmhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPNNmVKSzVyPUS2MlQzPTVizszN Mk\YV2FPT0WU
NUGC-3 MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTR4LkW3NFkh|ryP NIDI[5FUSU6JRWK=
T98G NF\XU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TiXGlEPTB;NEeuOVQ4KM7:TR?= MknaV2FPT0WU
OVCAR-8 NYXXSpVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\SVIxSUUN3ME20O{43QDNizszN MXHTRW5ITVJ?
LB2241-RCC MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIj0VGVKSzVyPUS3MlczPyEQvF2= NGrxVnBUSU6JRWK=
NCI-H358 NI\FbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvTdIM3UUN3ME20PE4yOTV{IN88US=> M{nNSXNCVkeHUh?=
PANC-08-13 NH6wfGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPlUINKSzVyPUS4MlE5PTNizszN NE\OR45USU6JRWK=
KP-N-YN NYTkVllQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTR6LkKxNFIh|ryP NYrv[WtqW0GQR1XS
NCI-H1755 Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\0SmlEPTB;NEiuNlczPiEQvF2= NHLGOoZUSU6JRWK=
NCI-N87 MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjVTWM2OD12OD6yPVkyKM7:TR?= MVfTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pFGFR2 / FGFR2 ; 

PubMed: 24968263     


PD173074 and MK2461 inhibit FGFR2 phosphorylation. Cells were treated for 1 hour with a titration of PD173074 as described in Materials and methods. Lysates were prepared and 50 ug protein was subjected to SDS-PAGE and western blotting with phospho Y653/654 FGFR and MAB6841 total FGFR2 antibody.

p-S6RP / p-PRAS40 / p-p105 NFKB / P105 NFKB / P50 NFKB / p-AMPK / p-CRK II / p-PDK1; 

PubMed: 24968263     


Time course of inhibition for multiple signaling proteins. NCI-H716 cells were treated with 100 nM PD173074 for the indicated times and signaling pathways were analyzed by SDS PAGE and western blotting. 100 nM PD173074 was selected because this amount caused full inhibition of pERK at the 2 hour time point. “p” indicates phosphoprotein, and the phosphorylation sites are listed in Methods. Terminology on the right side of figure groups proteins according to the time at which inhibition or protein loss occurs.

24968263
Growth inhibition assay
Cell viability; 

PubMed: 24968263     


B. PD173074 and MK2461 inhibit NCI-H716 cell growth. Cell lines were plated at 4000 cells/well and incubated overnight. NCI-H716 cells were treated with a titration of PD173074 as described in Materials and Methods. Cell growth was measured with Vialight reagent, and growth was presented relative to untreated cells. C. PD173074 and MK2461 selectively inhibit growth of NCI-H716 cells. Colon cancer cell lines listed were plated at 4000 cells/well and 24 hours later were treated with a titration of compounds. 4 days later cell growth was measured with vialight and IC50s were calculated from graph pad prism. 

24968263
In vivo Administration of PD173074 at 1 mg/kg/day or 2 mg/ka/day in mice can effectively block angiogenesis induced by either FGF or VEGF in a dose-dependent manner with no apparent toxicity. [1] PD173074 inhibits in vivo growth of mutant FGFR3-transfected NIH 3T3 cells in nude mice. Inhibition of FGFR3 by PD173074 delays tumor growth and increases survival of mice in a KMS11 xenograft myeloma model. [4] In the H-510 xenograft, oral aministration of PD173074 blocks tumor growth similar to that seen with single-agent cisplatin administration, increasing median survival compared with control sham-treated animals. In H-69 xenografts, PD173074 induces complete responses lasting >6 months in 50% of mice. These effects are correlated with increased apoptosis in excised tumors, but not a consequence of disrupted tumor vasculature. [5]

Protocol

Kinase Assay:[1]
- Collapse

In vitro kinase inhibition assays:

Assays using the full-length FGFR-1 kinase are performed in a total volume of 100 μL containing 25 mM HEPES buffer (pH 7.4), 150 mM NaCl, 10 mM MnCl2, 0.2 mM sodium orthovanadate, 750 μg/mL concentration of a random copolymer of glutamic acid and tyrosine (4:1), various concentrations of PD173074 and 60 to 75 ng of enzyme. The reaction is initiated by the addition of [γ-32P]ATP (5 μM ATP containing 0.4 μCi of [γ-32P]ATP per incubation), and samples are incubated at 25°C for 10 minutes. The reaction is terminated by the addition of 30% trichloroacetic acid and the precipitation of material onto glass-fiber filter mats. Filters are washed three times with 15% trichloroacetic acid, and the incorporation of [32P] into the glutamate tyrosine polymer substrate is determined by counting the radioactivity retained on the filters in a Wallac 1250 betaplate reader. Nonspecific activity is defined as radioactivity retained on the filters following incubation of samples without enzyme. Specific activity is determined as total activity (enzyme plus buffer) minus nonspecific activity. The concentration of PD173074 that inhibits FGFR-1 enzymatic activity by 50% (IC50) is determined graphically.
Cell Research:[4]
- Collapse
  • Cell lines: KMS11 and KMS18
  • Concentrations: Dissolved in DMSO, final concentrations ~100 nM
  • Incubation Time: 48 hours
  • Method: Cells are incubated with increasing concentrations of PD173074 in the presence of aFGF/heparin for 48 hours. The percentage of viable cells is determined by MTT.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Swiss Webster mice with induced corneal angiogenesis
  • Dosages: ~2 mg/kg/day
  • Administration: Administered intraperitoneally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (190.95 mM)
Water Insoluble
Ethanol '100 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 523.67
Formula

C28H41N7O3

CAS No. 219580-11-7
Storage powder
in solvent
Synonyms N/A
Smiles CCN(CC)CCCCNC1=NC2=NC(=C(C=C2C=N1)C3=CC(=CC(=C3)OC)OC)NC(=O)NC(C)(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the half-life of PD173074(S1264) in vivo?

  • Answer:

    According to literature research, PD173074 is given twice daily because it has a short half-life in vivo, please refer to the following link for detailed pharmacokinetic information (Supplementary Figure 8B): http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990281/#!po=50.0000.

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

Related FGFR Products

Tags: buy PD173074 | PD173074 supplier | purchase PD173074 | PD173074 cost | PD173074 manufacturer | order PD173074 | PD173074 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID